Search
BGB-DXP593
go.drugbank.com/drugs/DB16357InvestigationalBGB-DXP593 is a SARS-CoV-2 neutralizing antibody. … [L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants
Anumigilimab
go.drugbank.com/drugs/DB16359InvestigationalCSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. … [A225626] It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.[L27516]
Descartes-30
go.drugbank.com/drugs/DB16361Investigational[L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics. … Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.
Recombinant Human Thrombopoietin
go.drugbank.com/drugs/DB16364InvestigationalRecombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. … [A225691, A225696] This drug is used in the treatment of thrombocytopenia.
Treamid
go.drugbank.com/drugs/DB16365InvestigationalTreamid, also known as bisamide derivative of dicarboxylic acid (BDDA), is a complexing agent that has been found to chelate metal ions, including calcium, copper, iron, magnesium, and zinc. … It is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy
Categories: Heterocyclic Compounds, 1-RingAutologous peripheral blood-derived CD34+ cells
go.drugbank.com/drugs/DB16367ApprovedInvestigational[L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage). … Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. … [L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
Synonyms: Matrix M, Matrix-MGlofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigationalIt has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells. … Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively.
Categories: Bispecific CD20-directed CD3 T Cell EngagerCobolimab
go.drugbank.com/drugs/DB16372InvestigationalCobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP).